OTCPK:PDRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has PD-Rx Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PDRX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

PDRX

-4.9%

US Healthcare

-2.4%

US Market


1 Year Return

-24.6%

PDRX

17.9%

US Healthcare

12.0%

US Market

Return vs Industry: PDRX underperformed the US Healthcare industry which returned 17.2% over the past year.

Return vs Market: PDRX underperformed the US Market which returned 10.9% over the past year.


Shareholder returns

PDRXIndustryMarket
7 Day0%-4.9%-2.4%
30 Day15.4%-6.1%-6.5%
90 Day14.9%-0.8%8.4%
1 Year-24.6%-24.6%19.5%17.9%14.5%12.0%
3 Year-10.9%-45.5%20.8%15.5%34.8%25.8%
5 Year-28.5%-56.2%46.3%35.9%82.1%61.6%

Price Volatility Vs. Market

How volatile is PD-Rx Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 years ago | Simply Wall St

Financially Strong And High Value Stocks

Valuation

Is PD-Rx Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.73x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PDRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PDRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PDRX is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: PDRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PDRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PDRX is good value based on its PB Ratio (0.7x) compared to the US Healthcare industry average (2.6x).


Next Steps

Future Growth

How is PD-Rx Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PD-Rx Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has PD-Rx Pharmaceuticals performed over the past 5 years?

-102.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: PDRX is currently unprofitable.

Growing Profit Margin: PDRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PDRX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PDRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PDRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).


Return on Equity

High ROE: PDRX has a negative Return on Equity (-0.18%), as it is currently unprofitable.


Next Steps

Financial Health

How is PD-Rx Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: PDRX's short term assets ($7.6M) exceed its short term liabilities ($1.6M).

Long Term Liabilities: PDRX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PDRX is debt free.

Reducing Debt: PDRX has not had any debt for past 5 years.

Debt Coverage: PDRX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PDRX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is PD-Rx Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PDRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PDRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PDRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PDRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PDRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

US$59k

CEO Compensation


CEO

Robert Holsey (67 yo)

no data

Tenure

US$58,519

Compensation

Dr. Robert D. Holsey D.O., R.Ph. has been a Director of Pd-rx Pharmaceuticals Inc. since 1986 and serves as President, Chief Executive Officer and Chairman of the Board and a practicing physician. Dr. Hols ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PD-Rx Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PD-Rx Pharmaceuticals, Inc.
  • Ticker: PDRX
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$5.145m
  • Shares outstanding: 1.72m
  • Website: https://www.pdrx.com

Location

  • PD-Rx Pharmaceuticals, Inc.
  • 727 North Ann Arbor
  • Oklahoma City
  • Oklahoma
  • 73127
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PDRXOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1992

Biography

PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry. It offers branded and generic pharmaceuticals, unit dose products ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/26 06:04
End of Day Share Price2020/09/17 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.